SCHEMBL19973987

SCHEMBL19973987

O=C(NC1CCOc2c(C(=O)Nc3ccc(F)c(F)c3)cccc21)c1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 4/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 2/20 0.45
CRACR2A Q9BSW2 1/20 0.44
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
KCNK3 O14649 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
BRAF P15056 1/20 0.40
CSF1R P07333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21175567 1.00 L3MBTL1 (0.47) L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL19973525 0.90 HTT (0.43) RAB9ANPC1SMN1; SMN2TP53CRACR2A
SCHEMBL19973530 0.90 HTT (0.43) RAB9ANPC1SMN1; SMN2TP53CRACR2A
SCHEMBL21189487 0.84 MEN1 (0.42) ALDH1A1CYP11B1CYP11B2MEN1KMT2A
SCHEMBL21189329 0.84 MEN1 (0.42) ALDH1A1CYP11B1CYP11B2MEN1KMT2A
SCHEMBL19973433 0.84 TP53 (0.46) L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL19973432 0.84 TP53 (0.46) L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL19973586 0.84 TP53 (0.46) L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL19973565 0.83 KMT2A (0.46) L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL19973499 0.83 KMT2A (0.46) L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS L3MBTL1 2663/4885ALDH1A1 3241/4885RAB9A 1393/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS L3MBTL1 2663/4885ALDH1A1 3241/4885RAB9A 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.